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Abstract
Background: With the non-medical use of prescription opioids increasingly becoming a method of abuse in Canada,
the number of patients requiring methadone maintenance treatment (MMT) for opioid use disorder has increased
dramatically. The rate of cannabis use in this population is disproportionately high (~50 %). Because its use is generally
perceived as harmless, cannabis use is often not monitored during MMT. Current literature regarding the effects of
cannabis use on MMT is conflicting, and the presence and nature of an association has not been clearly established.
The primary objective of this review will be to conduct a systematic review of the literature and, if appropriate, a
meta-analysis to determine whether there is an association between cannabis use and MMT outcomes. A secondary
objective will be to perform subgroup analyses (by age, sex, method of cannabis measurement, and country) to
determine whether cannabis use differentially influences MMT outcomes within these subgroups.
Methods/design: The search will be conducted on the following electronic databases using a predefined search
strategy: MEDLINE, EMBASE, PsycINFO, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). Two
authors (LZ and MB) will independently screen articles using predetermined inclusion/exclusion criteria and will extract
data from included articles using a pilot-tested data extraction form. Disagreements at all stages of the screening process
will be settled through discussion, and when consensus cannot be reached, a third author (ZS) will be consulted. An
assessment of quality and risk of bias will be conducted on all included articles, and a sensitivity analysis will be used to
compare results of studies with high and low risk of bias. We will perform random- and fixed-effects meta-analyses, if
appropriate, with heterogeneity calculated using the I2 statistic and formal evaluation of publication bias.
Discussion: Results of this systematic review will elucidate the association between cannabis use and methadone
maintenance treatment outcomes. We will provide evidence that will be useful to clinicians regarding whether
monitoring cannabis use during MMT is advantageous for optimizing MMT outcomes.
Systematic review registration: PROSPERO CRD42015029372
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Background
There are an estimated 33 million opioid users globally
[1], which is markedly contributing to the global burden
of disease [2]. Illicit opioid use is associated with signifi-
cant personal health risks, such as accidental injury,
dependency, infectious disease [3], and potential for fatal
overdose, in addition to its effects on the social concerns
of healthcare costs, criminal activity, and employment
[2]. Although the prevalence of heroin use has remained
constant in Canada, a dramatic rise in the use of
prescription opioids has resulted in a surge in opioid
detoxification admissions from 2000 to 2004 [4]. In both
the USA and Canada, illicit use of prescription opioids
has become a significant contributor to emergency room
visits and mortality [5]. This changing landscape and
steady increase in problematic opioid use in North
America signals an urgent need for evidence-based
treatment practices.
Canada has witnessed a fivefold increase in patients on
methadone maintenance treatment (MMT) since the mid-
1990s [6]. MMT is an opioid substitution therapy and is
the most widely researched pharmacological treatment for
opioid use disorder [7]. Methadone is a long-acting
synthetic opioid intended to reduce cravings and with-
drawal symptoms without producing the euphoric effects
associated with illicit opioids [8]. Studies have shown this
treatment to be effective in decreasing illicit opioid use,
reducing criminal activity, and reducing mortality rates
among patients [7]. Although an overall efficacious treat-
ment for reducing illicit opioid use, MMT is limiting in
that it has high attrition rates [9] because it often requires
patients to be on the treatment for life [10].
Polydrug use is common among MMT patients [11, 12],
with cannabis consistently being the most commonly used
illicit drug in this population [13–15]. This may be due to
the fact that cannabis is generally perceived as harmless
[16]. While it may be the case that mortality directly
resulting from cannabis use is unlikely [2], associations
with other adverse health outcomes have been found. In
particular, regular cannabis use increases the risk of motor
vehicle accidents and respiratory problems and poses a
risk for dependency [17]. Long-term use is also associated
with lower school performance and decreased life satisfac-
tion [16]. Furthermore, cannabis use is associated with
adverse mental health outcomes. The strongest evidence
comes from studies on psychotic disorders, with a system-
atic review showing a strong, positive relationship between
incidence of psychosis and cannabis use, which increases
as frequency of cannabis use increases [18]. Studies have
also found associations with other psychiatric illnesses
including mood disorders (unipolar and bipolar) [19–21]
and anxiety (particularly panic disorder and social anxiety)
[22, 23]; however, evidence for a directional association
with these disorders is inconclusive. Nonetheless, it
remains a possibility that cannabis use during the treat-
ment of opioid addiction could influence its outcome.
Studies on the association between cannabis use and
MMT outcomes have produced conflicting results, with
some demonstrating beneficial effects on outcomes [14]
and others showing an association with adverse treat-
ment outcomes. For example, Wasserman et al. [24]
found that cannabis use at baseline and throughout the
study period was significantly associated with subsequent
heroin use during treatment, whereas Scavone et al. [14]
found that patients using cannabis during the study re-
ported significantly less daily expenditure on acquiring
opioids. Most studies, however, have failed to produce a
statistically significant association between cannabis use
and MMT retention or illicit opioid use [13, 25–28].
Epstein and Preston [26] found that cannabis use in-
creased other outcomes such as jail time and family
conflict, suggesting that its use during MMT may act in-
directly via social and lifestyle risk factors. The relation-
ship between cannabis use and MMT outcomes may also
include complex interactions with health behaviors. For
instance, depressive symptoms and illicit substance use
during MMT is significantly associated with a lack of HIV
medication adherence [20], which may in turn affect
MMT outcomes and overall health status among patients.
It remains unclear whether there is a true association
between cannabis use and MMT outcomes and to what
degree this association may be mediated by other
confounding variables. A systematic investigation and
evaluation of the studies is necessary, as well as the identi-
fication of any gaps in the literature. We hypothesize that
the use of cannabis in patients with opioid use disorder
treated with methadone is associated with poor response
to MMT as defined by illicit opioid use and length of
treatment retention. Evidence indicates that treatment re-
tention is a critical factor in MMT success, with research
suggesting that those in treatment for less than 90 days
resemble those receiving no treatment at all [29]. Indeed,
MMT dropout is significantly associated with drug use
relapse and other high-risk health behaviors [11] and is a
useful indicator of treatment response. We will also
consider secondary outcomes to evaluate risky health and
social behaviors including criminal activity, jail time,
polydrug use, injection drug use, needle sharing, and
unprotected sex. Isolating each outcome and controlling
for potential confounders will help to clarify the
association between cannabis use and MMT outcomes.
Objectives
The objective of this systematic review is to summarize
the existing literature examining the effects of cannabis
use on treatment outcomes during methadone mainten-
ance treatment in patients with opioid use disorder by
identifying and evaluating the current evidence.
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Specifically, our aims are as follows:
1. Summarize primary research to examine the
relationship between cannabis use and primary
methadone maintenance treatment outcomes
(treatment retention and illicit opioid use) and
secondary outcomes (criminal activity, jail time,
polydrug use, injection drug use, needle sharing,
and unprotected sex).
2. Combine statistical outcomes of the primary studies
in a meta-analysis, when appropriate.
3. Conduct subgroup analyses based on sex, method of
cannabis measurement, and geographical region of
study to explore potential confounders in the
relationship.
4. Critically appraise the existing literature and identify
areas requiring further research.
Methods and design
Search strategy
An experienced health sciences librarian (NB) will be
consulted when creating and implementing the search
strategy. The following databases will be searched from
their inception to present: MEDLINE/PubMed, EMBASE,
PsycINFO, and Cumulative Index to Nursing and Allied
Health Literature (CINAHL). Relevant articles will be
identified from the comprehensive search strategy using
all relevant search terms related to methadone mainten-
ance treatment and cannabis, and their medical subject
heading (MeSH) equivalents in varying combinations
(Table 1). A wide search will be conducted to include ti-
tles, abstracts, and keyword fields. Outcome variables will
not be included in the search strategy so as not to impose
unnecessary limitations on search results. The searches
will all be limited to human studies. Gray literature will
also be searched using ProQuest Dissertations and Theses
Global database. Finally, we will conduct a thorough hand
search of past reviews and reference lists of included
studies to identify potentially relevant articles that the
initial search strategy may not have captured.
Inclusion/exclusion criteria
This review will include published observational studies
or randomized controlled trials (RCTs) of the relation-
ship between cannabis use and methadone maintenance
treatment outcomes in any setting (hospital, outpatient,
or community-based). Included studies will measure
cannabis use at baseline for cross-sectional studies and
during treatment for cohort studies and RCTs, which
may be measured using objective measures (i.e., urine or
hair analyses) or self-reports.
Studies will be excluded if they do not measure at least
one of the primary or secondary outcomes of interest. If
cannabis use is measured as an outcome rather than a
predictor variable, it will be excluded. Many studies in
this domain report frequency of cannabis use as part of
the demographics of the sample, and as such, these will be
excluded as we cannot make any conclusions regarding its
direct association with MMT outcomes. Studies including
patients on opioid substitution therapy (i.e., buprenor-
phine or buprenorphine/naloxone) other than methadone
will be excluded. Furthermore, studies looking at patients
Table 1 Search strategy
Database Search strategy








9. Cannabis.mp. or marijuana*.mp.
10. THC.mp. or hash*.mp. or ganja.mp.
or hemp.mp. or bhang*.mp.
11. 1 or 2 or 3 or 4
12. 5 or 6 or 7 or 8 or 9 or 10
13. 11 an 12
14. Limit 13 to humans
EMBASE (n = 1761) 1. exp opiate substitution treatment/





7. exp “cannabis use”/
8. exp cannabis addiction/
9. exp cannabis smoking/
10. exp medical cannabis/
11. Cannabis.mp. or marijuana*.mp.
12. THC.mp. or hash*.mp. or ganja.mp.
or hemp.mp. or bhang*.mp.
13. 1 or 2 or 3 or 4 or 5
14. 6 or 7 or 8 or 9 or 10 or 11 or 12
15. 13 and 14
16. Limit 15 to humans




5. exp marijuana usage/
6. cannabis.mp. or marijuana*.mp.
7. THC.mp. or hash*.mp. or ganja.mp.
or hemp.mp. or bhang*.mp.
8. 1 or 2 or 3
9. 4 or 5 or 6 or 7
10. 8 and 9
11. Limit 10 to humans




5. (MH “Medical Marijuana”)
6. “marijuana” or “cannabis”
7. “THC” or “hash*” or “ganja” or
“hemp*” or “bhang*”
8. 1 or 2 or 3
9. 4 or 5 or 6
10. 7 and 8 (limiters – human)
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on methadone for anything other than treatment of opioid
use disorder (i.e., illicit methadone use or chronic pain
treatment) will be excluded. No age restrictions will be
applied, as opioid addiction affects people of all age
groups. There will be no other demographic limitations or
language restrictions.
Outcome measures
Two primary outcomes variables will be measured which
evaluate the success of methadone maintenance treatment.
These include illicit opioid use which may be measured in
any way (self-reports, urine toxicology, hair analysis), as
well as treatment retention. Treatment retention may be
measured as either proportion of individuals remaining in
treatment at the end of study or average length of time in
treatment. In addition to the MMT outcomes, secondary
outcomes will be considered which reflect the patients’
social and personal functioning and other drug use behav-
iors. These include criminal activity, jail time, polydrug use,
injection drug use, needle sharing, and unprotected sex.
Data management
All articles retrieved during the initial search will be
uploaded to Covidence, an online software system used
to manage systematic reviews and promotes collabor-
ation among authors. Training will be provided to all
members using the Covidence software. The review
team will define a set of inclusion and exclusion criteria,
and pilot test the title/abstract screening with the first
100 articles. Upon completion of title and abstract
screening, full-text articles will be uploaded to the
Covidence system for purposes of the full-text review.
Selection of studies
Two independent reviewers (LZ and MB) will complete
the initial title and abstract screening to identify eligible
articles using a predetermined criteria. Articles deemed
eligible will be retrieved for a full-text review. Any
disagreements during the screening process that cannot
be settled through discussion will be resolved by a third
party (ZS). Authors of the studies will be contacted if any
clarification or additional data is needed during the full-
text review to determine eligibility. For each phase of
screening, a kappa statistic will be calculated to determine
inter-rater agreements. A kappa value of 0.75 or greater
reflects excellent agreement [30]. Studies determined to
be ineligible will be excluded from the review. Reasons for
ineligibility and exclusion will be reported using the pre-
ferred reporting items for systematic reviews and meta-
analyses (PRISMA) [31] or meta-analysis of observational
studies in epidemiology (MOOSE) [32] flow diagrams.
Data extraction
The two reviewers (LZ and MB) will independently ex-
tract data from the included studies using a pilot-tested
data extraction form (see Additional file 1). To maximize
consistency, a calibration exercise will be performed
using articles not included in the review with the two re-
viewers prior to starting the data extraction phase. The
authors will extract the following information from each
study: publication details (name, author, year, journal,
and country), study design (type of study, participant in-
formation, inclusion criteria, and length of study), demo-
graphics (mean age, ethnicity, and sex), measurement of
cannabis (self-report, urinalysis, or hair analysis), out-
come measures, the main findings, and statistical results
(effect measures, p values, confidence intervals, etc.). If
multiple outcomes are reported, all of them will be
recorded so we can combine the studies with similar
outcome measurements. Authors will be contacted in
the case of missing or incomplete data.
Assessment of quality
Risk of bias in will be assessed by two independent
raters (LZ and MB) using the Newcastle-Ottawa Scale
(NOS) [33]. An adapted version of a modified NOS was
developed by Bawor et al. to be used to assess risk of
bias in observational studies [34]. This version includes
seven questions evaluating bias in four domains of biases:
selection bias, performance bias, detection bias, and infor-
mation bias. Risk of bias is measured on a scale of 0 (high
risk) to 3 (low risk). The adapted version has removed
items regarding the comparability of groups and suitable
follow-up for cohort and case-control studies, as these
items are not relevant for our topic of interest. The
Cochrane Collaboration tool will be used for randomized
controlled trials which assess risk of bias using six
domains: selection bias, performance bias, detection bias,
attrition bias, reporting bias, and other biases [35].
Quality of the literature will be measured using the
grading of recommendations, assessment, development,
and evaluation (GRADE) framework, which scores
articles based on five domains—risk of bias, publication
bias, consistency, directness, and precision [36]. These
findings will be summarized in a table, allowing for an
assessment of the confidence of the estimates. A
summary of the findings will be provided in a table to
easily compare the quality of studies included in this
review and allow for confidence of estimates.
Statistical analyses
All included studies will first be reviewed in a qualitative
summary, followed by a meta-analysis if possible. Studies
will be combined in a meta-analysis based on similarities
in study design and outcome measurements. Direct
estimates will be pooled separately based on study design,
Zielinski et al. Systematic Reviews  (2016) 5:139 Page 4 of 7
as pooling data from observational studies and RCTs is
cautioned against due to the inherent susceptibility of
observational studies to selection biases [37]. A random-
effects model for meta-analysis will be used to account for
the expected heterogeneity in the literature, which
assumes both within-study and between-study variability
to provide a more conservative estimate compared to a
fixed-effects model. These results will be presented in a
forest plot. In the case of missing data, we will attempt to
contact authors to obtain the relevant data. If the missing
data cannot be obtained, we will employ an imputation
method. We may also conduct a sensitivity analysis to
assess the impact of missing data on the overall treatment
effects. A sensitivity analysis will also be conducted to
compare the overall results of studies with high or low risk
of bias.
Heterogeneity will be calculated among pooled studies
using the I2 statistic. It is advised not to impose cut-off
values because the importance of heterogeneity depends
on a multitude of factors. However, Cochrane suggests
that a value <40 % may not represent a notable amount
of heterogeneity [37]. Thus, possible sources of clinical
heterogeneity will be examined given an I2 statistic > 40 %,
and subgroup analyses will be performed. Possible sources
of heterogeneity include age, sex, method of cannabis
measurement, and country, and these will be investigated
using subgroup analyses.
Subgroup analyses
Subgroups are identified a priori so we can make stronger
inferences about the effects of the subgroups [38].
Subgroup analyses will be conducted on the following
variables: age, sex, method of cannabis measurement, and
country. Drug addiction is a disorder that afflicts people of
all ages, and thus no age restrictions will be placed on the
articles in this review. However, there are differences in
the biological and social mechanisms involved with youth
and adults, so cannabis may differentially influence treat-
ment outcomes in the two populations. Because a consist-
ent age range is not used to define youth in MMT studies
[28, 39, 40], MMT studies will be included in the subgroup
analysis if the authors specify that they are investigating
youths or adolescents.
Methadone maintenance treatment has been found to
differentially affect men and women [34], and prevalence
of cannabis use tends to be higher in males [41]. However,
females display a stronger dose-dependent effect from
cannabis compared to males, with significantly lower men-
tal quality of life as dosage increases [42]. Furthermore,
women demonstrate a faster trajectory towards the devel-
opment of cannabis use disorder [43]. Thus, particularly
among heavy cannabis users, we expect treatment out-
comes in women to be more negatively impacted by can-
nabis use. Stratifying these populations using a subgroup
analysis may reveal differences in the way cannabis use
affects MMT outcomes for males and females.
We will also compare results of studies that use subject-
ive or objective measures of drug use. Studies have shown
that a large number of patients in treatment for addiction
underreport drug use [44], whether intentionally or not,
and thus objective measures of drug use, such as urine or
hair analysis, may provide a more accurate estimate of
cannabis use in the population. Therefore, we expect to
find a stronger association between objective measures of
cannabis and MMT outcomes compared to studies using
subjective measures.
Finally, any potential differences found between studies
from different regions of the world or different decades will
be qualitatively commented on and compared to current
literature on drug use patterns considering the varied
pattern of drug use across the world [2]. Specifically, North
America has the highest proportion of cannabis use and
high rates of opioid use, largely due to the surge in non-
medical use of prescription opioids [1]. Illicit drug use is
considerably less in Europe, with lower rates of cannabis
use compared to North America, as well as significantly
less opioid use [1]. On the other hand, more than half of
the world’s opioid-using population lives in Asia, although
cannabis rates are below the global average [1]. These
different patterns of illicit drug use around the world
signify that different societal mechanisms are at play, which
may impact treatment outcomes for drug addiction.
Presenting and reporting of results
This systematic review will be reported in accordance
with the PRISMA guidelines [31]. Additionally, we
expect to include many observational studies, in which
case these will be reported following the MOOSE guide-
lines [32]. A flow chart will be used to display the
selection of articles with reasons for exclusion. Study
characteristics and measured outcomes will be compiled
into summary tables. An Egger’s plot will be included to
examine potential publication bias in the selected
studies. If a meta-analysis is possible, results will be
presented in a forest plot. The current protocol follows
the preferred reporting items for systematic review and
meta-analysis protocols (PRISMA-P) statement (see
Additional file 2 for checklist) [45].
Discussion
Using evidence from this systematic review, we expect to
make conclusions regarding the presence of an association
between cannabis use and methadone maintenance treat-
ment outcomes. Systematically reviewing the literature
will contribute to our understanding of the mechanisms
involved in treatment retention and drug relapse in
patients with opioid use disorder. We will also be inves-
tigating cannabis use and its association with other
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outcomes related to overall social and physical well-being
in MMT patients.
To our knowledge, this will be the first systematic
review conducted on this topic. Given the current trend
of cannabis being approved in many US states and the
move towards a more liberal use in Canada, it is impera-
tive that these policy decisions are evidence-based. The
findings of this systematic review will also be of value to
clinicians administering methadone maintenance treat-
ment to patients with opioid use disorder, as it will pro-
vide evidence regarding whether monitoring cannabis
use during MMT is necessary, and how it may predict a
patient’s treatment outcomes.
Additional files
Additional file 1: Data extraction form. (PDF 7 kb)
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